POST Online Media Lite Edition



 

Lilly to buy cancer drug developer AurKa Pharma for up to $575 million

Staff Writer |
Eli Lilly and Company will buy AurKa Pharma in a deal potentially worth up to $575 million.

Article continues below




AurKa Pharma will receive $110 million upfront and is eligible to earn up to $465 million more if it achieves regulatory and sales milestones.

AurKa’s chief drug under development was discovered by Lilly, but the drugmaker sold the compound in 2016 to TVM Capital Life Science, which established AurKa.

The drug, AK-01, is being studied in early-stage trials to treat multiple types of solid tumors.


What to read next

Eli Lilly & Co. to invest $850m in U.S. operations
Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 billion
EU launches probe into Aspen Pharma cancer drug pricing